CRTI Translational Research Grants
The objective of the CRTI Translational Research Grants is to partner Masonic Cancer Center basic/translational and clinical scientists so as to foster the development of novel experimental therapeutic agents and to facilitate their testing in institutional Phase I/II and IND clinical trials. These grants will provide targeted investments to promising translational studies with the goal of opening a clinical trial within 36 months.
Grant Program Contacts
Application process, requirements, eligibility:
Katie Thomas
Research Development Coordinator
612-624-8679
mccgrant@umn.edu
Applicability of research:
Deepa Kolaseri, PhD
dkolaser@umn.edu
Julia Davydova, MD, PhD
Department of Surgery, Medical School
Developing more effective regulatory T cell therapeutics using non-viral control of gene expression
Keli Hippen, PhD, Department of Pediatrics, Medical School
Bruce Blazar, MD, Department of Pediatrics, Medical School
Endoglin, A Potential Novel Target for AML
Rita Perlingeiro, PhD, Department of Medicine, Medical School
Sarah Cooley, MD, Department of Medicine, Medical School
Edward Greeno, MD, Department of Medicine, Medical School
USP14 as an Independent Prognostic Biomarker and Therapeutic Target for Recurrent Endometrial Cancer
Martina Bazzaro, PhD, Department of Obstetrics, Gynecology and Women’s Health, Medical School
Melissa Geller, MD, Department of Obstetrics, Gynecology and Women’s Health, Medical School
IL-15 Superagonist ALT-803 for Treatment of Advanced Staged Ovarian Cancer
Melissa Geller, MD, Department of Obstetrics, Gynecology and Women’s Health, Medical School
Jeffrey Miller, MD, Department of Medicine, Medical School
eBAT (Epidermal Growth Factor Receptor (EGFR) Bispecific Angiotoxin) for the Treatment of EGFR Positive Malignancies
Brenda Weigel, MD, Department of Pediatrics, Medical School
Evidio Domingo-Musibay, MD, Department of Medicine, Medical School